Company intelligence / Profile preview
Wayshine Biopharm
Shanghai, Shanghai, Chinawayshinebiopharm.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
WSD-0922, their lead candidate, is currently in Phase 2 clinical trials for non-small cell lung cancer. It previously received IND approval from FDA with Phase 1 clinical trials conducted at Mayo Clinic. WSD-0628 has received IND approval for glioma treatment. WSD-1227 is in preclinical development for brain metastases.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule drugsBiological products
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Beyond the preview
Go deeper on Wayshine Biopharm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Wayshine Biopharm.